Transforming Immunotherapy for Hematologic Disorders
Treatment
Shielded Cell & Immunotherapy Pairs™
Using our cell-shielding technology and paired immunotherapies, we aim to develop curative therapies for patients with hematologic disorders.
Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy cells.
Because the healthy cells are protected, the immunotherapy can be safely administered to boost engraftment or treat minimal residual disease.


Technology
Cell Shielding
We use gene editing tools to insert novel protein variants into HSCs or other types of cells, allowing the cells to maintain their function while making them resistant to depletion by the paired immunotherapy.
Our shielding technology has proven to be effective in shielding cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.